Martin Gerl

Title: Martin Gerl: Innovator in Immunologic Assays and Peptide Derivatives

Introduction

Martin Gerl is a notable inventor based in Niedernhausen, Germany. He has made significant contributions to the field of immunology and biochemistry, holding 2 patents that showcase his innovative spirit and expertise.

Latest Patents

Gerl's latest patents include an immunologic assay designed to determine C-peptide containing impurities in samples of human insulin and its derivatives. This invention relates to a process for detecting or determining a C-peptide-containing impurity in a sample of recombinantly produced human insulin or a derivative thereof, utilizing a non-radioactive assay. Another significant patent involves low molecular weight peptide derivatives that act as inhibitors of the laminin/nidogen interaction. This patent details a process for their preparation, pharmaceutical compositions derived from them, and their applications in pharmaceuticals and identifying inhibitors of the laminin/nidogen interaction.

Career Highlights

Throughout his career, Martin Gerl has worked with prominent companies in the pharmaceutical industry, including Aventis Pharma Deutschland GmbH and Sanofi-Aventis Deutschland GmbH. His work in these organizations has allowed him to contribute to advancements in medical science and technology.

Collaborations

Gerl has collaborated with esteemed colleagues such as Hans Ulrich Stilz and Gary A Flynn, further enhancing his research and development efforts in the field.

Conclusion

Martin Gerl's innovative work in immunologic assays and peptide derivatives has made a lasting impact on the pharmaceutical industry. His contributions continue to influence advancements in medical research and applications.